Hospice inpatient deep vein thrombosis detection (HIDDen) in advanced non-malignant diseases: a longitudinal pilot study by Clare, White et al.
1 
 
TITLE PAGE 
 
TITLE 
Hospice Inpatient Deep vein thrombosis Detection (HIDDen) in advanced non-
malignant diseases”: a longitudinal pilot study 
AUTHORS 
Clare White MD, Northern Ireland Hospice, Belfast, Northern Ireland, United 
Kingdom and Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK 
Prof Simon Noble MD, Marie Curie Palliative Care Research Centre, Cardiff 
University, Cardiff, Wales, UK 
Flavia Swan PhD, Wolfson Palliative Care Research Centre, Hull York Medical 
School, University of Hull, Hull, UK 
Prof Max Watson MPhil, Director Project ECHO, Hospice UK, London, UK 
Victoria Allgar PhD, Wolfson Palliative Care Research Centre, Hull York Medical 
School, University of York, York, UK 
Eoin Napier FRCR, Belfast Health and Social Care Trust, Belfast, Northern Ireland, 
UK 
Prof Annmarie Nelson PhD, Marie Curie Palliative Care Research Centre, Cardiff 
University, Cardiff, Wales, UK 
Prof Miriam Johnson MD, Wolfson Palliative Care Research Centre, Hull York 
Medical School, University of Hull, Hull, UK 
 
Corresponding author: 
Dr Clare White, Consultant Palliative Medicine, Northern Ireland Hospice, 74 
Somerton Rd, Belfast, Northern Ireland, United Kingdom 
2 
 
Email: cwhite@nihospice.org 
Tel:07790697205  
 
FUNDING SOURCE 
The HIDDen study was funded by the NIHR Research for Patient Benefit programme 
(PB-PG-0614-34007). The views expressed are those of the authors and not 
necessarily those of the NHS, the NIHR or the Department of Health and Social 
Care. The funder had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all 
the data in the study and has final responsibility for the decision to submit for 
publication.  
 
SN and AN’s posts are funded by Marie Curie Cancer Care core grant funding (grant 
reference MCCC-FCO-17-C). 
 
DECLARATION OF INTERESTS 
MW designed and teaches the Focussed Abdominal Ultrasound in Palliative Care 
training programme, running since 2007, which trained the research nurses for this 
study. SN has received speakers bureau fees from Pfizer, Daiichi Sankyo, Bayer and 
Advisory Board fees from Daiichi Sankyo. Other authors declare no conflicts of 
interest. 
 
AUTHOR CONTRIBUTIONS 
Concept: CW, MJJ, SN, MW; Design: CW, MJJ, SN, MW, AN, EN, VA; Data 
collection and management; FS, VA, MJJ, CW, SN, EN; Radiological review and 
training: EN, MW; Patient and public involvement leads: AN, SN; Data analysis: FS, 
3 
 
VA; First draft of manuscript: CW; Critical revision of manuscript: CW, MJJ, VA, FS: 
Contribution to and approval of final manuscript: all authors 
MJ, VA, and FS had access to all raw data. EN had access to all scan images. 
DATA SHARING 
Data can be accessed by contacting the corresponding author. 
 
Word count 1497 (excluding table) 
 
Licence for Publication 
The Corresponding Author has the right to grant on behalf of all authors and 
does grant on behalf of all authors, an exclusive licence (or non exclusive for 
government employees) on a worldwide basis to the BMJ Publishing Group 
Ltd to permit this article (if accepted) to be published in BMJ Supportive and 
Palliative Care and any other BMJPGL products and sublicences such use and 
exploit all subsidiary rights, as set out in our licence 
(http://group.bmj.com/products/journals/instructions-for-authors/licence-
forms).  
4 
 
ABSTRACT 
Objectives 
To gain preliminary data regarding the prevalence of proximal deep vein thrombosis 
(DVT) in those with non-malignant conditions admitted to  specialist palliative care 
units (SPCUs).  
Methods 
Data were collected as part of a prospective longitudinal observational study in five 
SPCUs in England, Wales and Northern Ireland (Registration:  ISRCTN97567719) to 
estimate the prevalence of proximal femoral vein DVT in people admitted to SPCUs. 
The primary outcome for this exploratory sub-study was the prevalence of DVT in 
patients with non-malignant palliative conditions. Consecutive consenting adults 
underwent bilateral femoral vein ultrasonography within 48 hours of admission. Data 
were collected on symptoms associated with venous thromboembolism. Patients 
were ineligible if estimated prognosis was less than five days. Cross-sectional 
descriptive analysis was conducted on baseline data and prevalence estimates 
presented with 95% confidence intervals. 
Results 
1390 patients were screened, 28 patients had non-malignant disease and all were 
recruited. Mean age 68·8 (SD 12·0), range 43 to 86 years; men 61%; survival mean 
86 (SD 108.5) range 1 to 345 days. No patient had a history of venous 
thromboembolism.  Four (14%) were receiving thromboprophylaxis. Of 22 evaluable 
scans, 8 (36%, 95% CI 17% to 59%) showed femoral vein DVT. Level of reported 
relevant symptoms (leg oedema, leg pain, chest pain, breathlessness) were high 
irrespective of the presence of DVT. 
Conclusion 
Our exploratory data indicate one in three people admitted to an SPCU with non-
malignant disease had a femoral vein DVT. Although definitive conclusions cannot 
be drawn, these data justify a larger prospective survey. 
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INTRODUCTION 
Venous thromboembolism (VTE); deep venous thrombosis (DVT) and pulmonary 
embolism (PE)) is the commonest preventable cause of hospital death(1), and 
prevention of hospital-acquired thrombosis is the number one hospital patient safety 
improvement strategy globally(2). Data on prevalence rates of VTE in different 
patient populations are scarce. In general medical units in non-critically ill patients, 
prevalence estimates are between 1.7% and 2.6% (3, 4) and higher (7.8%) in the 
critically ill (5). A prevalence of asymptomatic DVT of 5.5% (95% CI 3.1-9.5) in adults 
and 17.8% (95% CI 8.5-32.6) among patients over 80 years was found using 
compression ultrasound on hospital admission (6). We recently published data 
showing a prevalence of femoral DVT in patients with cancer admitted to a specialist 
palliative care unit (SPCU) of 34%, (CI 28% to 40%) (7) but there are no studies to 
our knowledge of the prevalence in patients with non-malignant disease admitted to 
this setting.   
Current clinical guidelines for patients hospitalized with acute illness recommend 
pharmacological thromboprophylaxis (8). However, patients with a life expectancy of 
less than 3 months were excluded systematically from studies informing these 
guidelines. Most people with palliative conditions, particularly non-malignant ones, 
will be admitted to hospital where they will receive thromboprophylaxis routinely. 
Only a small proportion will be admitted to SPCUs where thromboprophylaxis is a 
matter of debate; the primary focus of palliative care being symptom control, not 
survival (9), and few prescribe thromboprophylaxis routinely (10-12).  
The prevalence and clinical relevance of femoral vein DVT in people with advanced 
non-malignant disease, alongside the risks and benefits of anticoagulation in these 
patients  is unknown. It is also unknown whether current practice in hospitals 
represents over-treatment and therefore the unnecessary risks of anticoagulation, or 
if current practice in SPCUs represents under-treatment with risk of symptomatic 
VTE.  
Although SPCU services have traditionally been for people with cancer, services are 
extending to people with non-malignant disease. Therefore it is important to 
understand the relevance of thromboprophylaxis in this group of patients in this 
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setting. We conducted this study to gain exploratory data regarding the prevalence of 
proximal DVT in those with non-malignant conditions admitted to SPCUs to 
determine whether a larger study was warranted.  
METHODS 
Study design and participants 
Data were collected as part of a prospective multicentre longitudinal observational 
study to estimate the prevalence of proximal femoral vein DVT in people admitted to 
SPCUs. Methods are described in detail in the presentation of findings in people with 
cancer (7). This report presents the cross-sectional analysis of the baseline data and 
survival in the sub-group of patients with non-malignant disease. 
Participants were enrolled to the parent study between 20/06/2016 and 16/10/2017. 
Eligible patients were consecutive adults, aged 18 and over, admitted to one of five 
SPCUs across England (n=1), Wales (n=1) and Northern Ireland (n=3), able to give 
fully informed written consent or with an appropriate consultee, and no physical 
impediment to femoral vein ultrasound examination. Patients with a clinician-
estimated prognosis of five days or less, insufficient mental capacity and no 
appropriate consultee, or insufficient English/Welsh to provide consent were 
excluded.  
In this sub-study, participants with non-malignant disease were included in the 
analysis. 
Institutional and ethical (Yorkshire & the Humber - Leeds West Research Ethics 
Committee; 16/YH/0045) approvals were granted prior to recruitment and the study 
was registered (ISRCTN97567719). 
Procedures 
Participants had assessments performed by a research nurse within 48 hours of 
admission.  
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Study outcome measures included: i) bedside femoral and popliteal vein assessment 
by ultrasound, ii) clinical symptoms of venous thromboembolism (leg oedema, leg 
pain, chest pain and breathlessness).   
Bilateral femoral and popliteal vein ultrasound scans were undertaken at the bedside 
by a research nurse within 48 hours of admission to a SPCU.  All scans were 
digitally recorded and reviewed by the study radiologist (EN) who was the final 
arbiter of the presence of DVT or no DVT. 
Survival was noted from the clinical record until the last participant had completed 
the three weeks follow up period of the parent study. 
Outcomes 
The primary outcome of the study was the prevalence of DVT. Secondary outcomes 
were symptoms attributable to DVT and survival.  
Statistical analysis 
Participant characteristics are summarised using descriptive analyses using mean 
(SD), minimum-maximum, or n (%), as appropriate.  The prevalence (within 48 hours 
of SPCU admission) is expressed as a percentage with associated 95% confidence 
intervals (CI).  
The study is reported in accordance with Strengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) statement (13). 
Role of the funding source 
The trial was funded by a competitive peer-reviewed grant from the National Institute 
Health Research (Research for Patient Benefit). The funder had no role in study 
design, data collection, data analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the study and has final 
responsibility for the decision to submit for publication. 
RESULTS 
Participant characteristics 
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1390 patients were screened between 20/06/2016 and 16/10/2017. All 28 patients 
with non-malignant disease were recruited (full flow chart available (7)), with a mean 
age 68·8 (SD 12·0), range 43 to 86 years. Other characteristics are shown in Table 
1. All participants were admitted only once during the study period.  No patient had a 
history of VTE (DVT or PE), and only 3 (10.7%) had a family history of VTE.  None 
were taking anticoagulation for secondary prevention of VTE or were wearing anti-
thromboembolic stockings. Documented risk factors for VTE included acute medical 
illness in the last 12 weeks (12, 42.9%), surgery in last 12 weeks (1, 3.6%), and 
bedbound during the last 12 weeks (3, 10.7%).  The Well’s deep vein thrombosis 
score was “likely” (≥ 2) for 7 (25%). Two-thirds (18, 64%) died during the study 
period and 10 (36%) were still alive at last follow up (mean survival 86 (SD 108.5) 
range 1 to 345 days).  
Table 1 Demographic Data of Participants  
  Number % 
Gender Male 17 61% 
Female 11 39% 
Diagnosis Chronic Obstructive Pulmonary Disease 10 36% 
Interstitial Lung Disease 2 7% 
Congestive Cardiac Failure 3 11% 
Motor Neurone Disease 6 21% 
Parkinson’s Disease 1 3.5% 
Renal Failure 1 3.5% 
Hepatic Failure 1 3.5% 
Other  4 14.5% 
Ethnicity White 28 100% 
Smoking history Current smoker 6 22% 
Ex-smoker 16 57% 
Never smoked 6 21% 
 
Co-morbidities 
Yes 24 86% 
No 4 14% 
Yes 4 14% 
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Anticoagulation 
thromboprophyla
xis 
No 24 86% 
 
 
Prevalence of femoral vein deep vein thrombosis at admission  
Doppler ultrasound scans were conducted on all 28 patients. The radiologist 
categorised them as “DVT present” (8, 29%), “no DVT” (14, 50%), “unable to 
evaluate” (4, 14%), data missing (2, 7%).  Of the 22 evaluable scans, 8 (36%, 95% 
CI: 17% to 59%) showed femoral vein DVT. None of the patients with a family history 
of VTE had a positive DVT Doppler baseline scan. None of the patients with a DVT 
at baseline were receiving anticoagulation medication. 
Associations with symptoms 
10 (36%) reported lower limb oedema and 18 (64%) reported lower limb pain.  Of the 
8 patients with a DVT, 4 (50%) reported lower limb oedema and 3 (38%) reported 
lower limb pain.  
10 (36%) reported chest pain and 25 (89%) reported breathlessness.  Of the 8 
patients with a DVT, 3 (38%) reported chest pain and all (100%) reported 
breathlessness. 
Of the 8 patients with a DVT at baseline, 3 (38%) had had an acute medical illness in 
the last 12 weeks and 1 (12.5%) had been bedbound in the last 12 weeks.  
Wells Score 
When considering if a positive (or ‘likely’) Wells score predicted the likelihood of 
being diagnosed with a DVT, there was no significant difference (p=0.240) between 
the Wells score and those with or those without a DVT. In those who were diagnosed 
with a DVT only 2/8 (25%) had a Wells score ‘likely’, and in those with no DVT 1/14 
(7%) had a Wells score ‘likely.’ 
DISCUSSION 
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The number of patients in this study are relatively small but bedside conducted 
compression ultrasonography identified femoral DVT in approximately one in three 
patients, none of which had been identified as part of their clinical care.  These 
figures are higher than estimates in the general medical population (3,4,6), and 
similar to those in the cancer population admitted to a SPCU reported in the parent 
study (7). This raises the question of whether prevalence of DVT in people with non-
malignant disease increases at the end of life. The sample size was too small to 
explore the clinical relevance with regard to symptoms and survival. As the parent 
study failed to show a relationship between symptoms (other than leg oedema), 
survival or thromboprophylaxis and the presence of DVT in people with advanced 
cancer, these data justify a larger study. The larger study should aim to determine if 
VTE prevalence is greater in advanced non-malignant disease admitted to a SPCU 
compared with those in general medical wards, and if these are associated with 
greater symptom burden or reduced survival.   
Strengths and limitations 
The numbers of patients in this study were small allowing only preliminary data.  
However, this pragmatic multicentre study with broad entry criteria included a range 
of non-malignant conditions, representative of the non-malignant SPCU population. 
To optimize recruitment, compression ultrasonography was conducted at the 
bedside by trained research nurses and independently validated by a consultant 
radiologist. Distal DVT and PE were not sought, so these results are likely to 
underrepresent the true incidence of VTE.  
Clinical and research implications 
Our preliminary data indicate a high prevalence of femoral DVT at the point of 
admission to SPCUs. Firm conclusions cannot be drawn, but these findings call for a 
larger prospective survey to be conducted. 
CONCLUSION 
Our exploratory data indicate that when patients with non-malignant disease as their 
primary palliative diagnosis were admitted to SPCUs, one in three had a femoral vein 
DVT.  This is similar to the prevalence found in those with a malignant diagnosis. 
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Although definitive conclusions cannot be drawn, these data justify a larger 
prospective survey to confirm or refute the figures, and explore whether the 
presence of DVT in this population has any impact on symptoms or survival. 
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